Efficacy and safety of Amrith Noni Arthoplus in osteoarthritis: a double-blinded, randomized clinical trial

Background: Osteoarthritis (OA) is a chronic, degenerative joint disorder marked by pain, inflammation, and impaired mobility, significantly affecting quality of life. Current treatments often provide limited relief and may have adverse effects with long-term use. This study aimed to evaluate the efficacy and safety of Amrith Noni Arthoplus in individuals with OA through a double-blinded, randomized clinical trial. Methods: This double-blind, randomized, placebo-controlled study evaluated the efficacy and safety of Amrith Noni Arthoplus, an herbal formulation containing Morinda citrifolia (Noni) as the primary ingredient, in 40 patients with osteoarthritis (OA). Efficacy was evaluated using the visual analog scale (VAS) for pain intensity, 6-minute walk test, stair climb test, physician and subject global assessments (PGA/SGA), serum biomarkers (hs-CRP, calcium, phosphorus, magnesium, vitamin D3), and bone mineral density (BMD) via DEXA scans. Safety was assessed through vital signs, haematology, liver and kidney function tests, and adverse event monitoring. Results: The active group demonstrated significant improvements in pain intensity (33.82% reduction in VAS scores, p<0.0001), physical function (14.17% increase in walking distance, p<0.0001), and stair climb time (12.75% reduction, p<0.0001) compared to the placebo group. Serum biomarkers, including hs-CRP (31.33% reduction, p<0.0001) and bone health markers (calcium, phosphorus, magnesium, vitamin D3), showed significant improvements. BMD increased by 25.48% in the active group (p<0.0001), while the placebo group experienced an 18.10% decline (p=0.002). No adverse events were reported, and all safety parameters remained within normal limits. Conclusions: Amrith Noni Arthoplus significantly alleviates OA symptoms, improves physical function, and enhances bone health, demonstrating its potential as a safe and effective complementary therapy for OA management.

Authors

Institutions

Publication Details

Journal
International Journal of Basic & Clinical Pharmacology
Published
2025-08-22
DOI
https://doi.org/10.18203/2319-2003.ijbcp20252574
Primary Topic
Morinda citrifolia extract uses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of Amrith Noni Arthoplus in osteoarthritis: a double-blinded, randomized clinical trial

Manoj Kumar Singh, Anil Kumar Nagraj, Sourabh Giri Baballi Umeshgiri, Radhika Hollehonnuru Meghraj et al.
2 links
International Journal of Basic & Clinical Pharmacology
Morinda citrifolia extract uses
article

Efficacy and safety of Amrith Noni Arthoplus in osteoarthritis: a double-blinded, randomized clinical trial

Manoj Kumar Singh, Anil Kumar Nagraj, Sourabh Giri Baballi Umeshgiri, Radhika Hollehonnuru Meghraj, A. K. Srinivasamurthy
article en

Abstract

Background: Osteoarthritis (OA) is a chronic, degenerative joint disorder marked by pain, inflammation, and impaired mobility, significantly affecting quality of life. Current treatments often provide limited relief and may have adverse effects with long-term use. This study aimed to evaluate the efficacy and safety of Amrith Noni Arthoplus in individuals with OA through a double-blinded, randomized clinical trial. Methods: This double-blind, randomized, placebo-controlled study evaluated the efficacy and safety of Amrith Noni Arthoplus, an herbal formulation containing Morinda citrifolia (Noni) as the primary ingredient, in 40 patients with osteoarthritis (OA). Efficacy was evaluated using the visual analog scale (VAS) for pain intensity, 6-minute walk test, stair climb test, physician and subject global assessments (PGA/SGA), serum biomarkers (hs-CRP, calcium, phosphorus, magnesium, vitamin D3), and bone mineral density (BMD) via DEXA scans. Safety was assessed through vital signs, haematology, liver and kidney function tests, and adverse event monitoring. Results: The active group demonstrated significant improvements in pain intensity (33.82% reduction in VAS scores, p<0.0001), physical function (14.17% increase in walking distance, p<0.0001), and stair climb time (12.75% reduction, p<0.0001) compared to the placebo group. Serum biomarkers, including hs-CRP (31.33% reduction, p<0.0001) and bone health markers (calcium, phosphorus, magnesium, vitamin D3), showed significant improvements. BMD increased by 25.48% in the active group (p<0.0001), while the placebo group experienced an 18.10% decline (p=0.002). No adverse events were reported, and all safety parameters remained within normal limits. Conclusions: Amrith Noni Arthoplus significantly alleviates OA symptoms, improves physical function, and enhances bone health, demonstrating its potential as a safe and effective complementary therapy for OA management.

International Journal of Basic & Clinical PharmacologyVol. 14(5)
Central University of Tibetan Studies (IN), Galena Biopharma (United States) (US)
Openalex Percentile: Top 66%
Morinda citrifolia extract uses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.